分红方面，佐力药业A股上市后累计派现14.42亿元。近三年，累计派现9.42亿元。 机构持仓方面，截止2025年9月30日，佐力药业十大流通股东中，创新药（159992）位居第八大流通股 东，持股685.49万股，相比上期增加28.07万股。南方中证1000ETF（512100）位居第十大流通股东，持 股641.72万股，相比上期减少5.88万股。中欧责任投资混合A（009872）退出十大流通股东之列。 声明：市场有风险，投资需谨慎。本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本文 出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 责任编辑：小浪快报 2月24日，佐力药业涨1.75%，成交额1.60亿元。两融数据显示，当日佐力药业获融资买入额1847.99万 元，融资偿还2125.40万元，融资净买入-277.40万元。截至2月24日，佐力药业融资融券余额合计5.95亿 元。 融资方面，佐力药业当日融资买入1847.99万元。当前融资余额5.92亿元，占流通市值的5.00%，融资余 额超过近一年70%分位水平，处于 ...

Core Viewpoint - Zhaoli Pharmaceutical has shown a mixed performance in financing activities and stockholder dynamics, with significant revenue growth and profit increase reported for the year 2025. Financing Activities - On February 3, Zhaoli Pharmaceutical's financing buy-in amounted to 18.73 million yuan, while financing repayment was 19.85 million yuan, resulting in a net financing outflow of 1.11 million yuan [1] - As of February 3, the total financing and securities balance for Zhaoli Pharmaceutical was 604 million yuan, with the financing balance accounting for 5.03% of the circulating market value, indicating a high level compared to the past year [1] - The company had a securities lending balance of 2.75 million yuan, with a lending volume of 162,000 shares, also reflecting a high level compared to the past year [1] Company Performance - For the period from January to September 2025, Zhaoli Pharmaceutical achieved an operating income of 2.28 billion yuan, representing a year-on-year growth of 11.48% [2] - The net profit attributable to the parent company for the same period was 510 million yuan, showing a year-on-year increase of 21.00% [2] Shareholder Dynamics - As of September 30, 2025, the number of shareholders for Zhaoli Pharmaceutical reached 41,400, an increase of 7.31% compared to the previous period [2] - The average circulating shares per person decreased by 6.82% to 14,562 shares [2] - The company has distributed a total of 1.442 billion yuan in dividends since its A-share listing, with 942 million yuan distributed in the last three years [3]

Core Viewpoint - Zhaoli Pharmaceutical has shown a mixed performance in stock price and financial metrics, with a notable increase in revenue and net profit year-on-year, indicating potential growth in the pharmaceutical sector [1][2]. Financial Performance - As of September 30, 2025, Zhaoli Pharmaceutical achieved a revenue of 2.28 billion yuan, representing a year-on-year growth of 11.48% [2]. - The net profit attributable to shareholders for the same period was 510 million yuan, reflecting a year-on-year increase of 21.00% [2]. - Cumulative cash dividends since the company's A-share listing amount to 1.442 billion yuan, with 942 million yuan distributed over the past three years [3]. Stock Performance - On January 13, 2025, Zhaoli Pharmaceutical's stock price increased by 2.10%, reaching 16.98 yuan per share, with a trading volume of 234 million yuan and a turnover rate of 2.31% [1]. - Year-to-date, the stock price has risen by 5.07%, while it has seen a decline of 7.31% over the past 20 days and 8.95% over the past 60 days [1]. Shareholder Structure - The number of shareholders as of September 30, 2025, was 41,400, an increase of 7.31% from the previous period [2]. - The average number of circulating shares per shareholder decreased by 6.82% to 14,562 shares [2]. - Among the top ten circulating shareholders, the "Innovation Drug" fund increased its holdings by 28.07% to 6.8549 million shares, while the "Southern CSI 1000 ETF" reduced its holdings by 5.88% to 6.4172 million shares [3].

Group 1 - On December 29, Zhaoli Pharmaceutical experienced a decline of 2.21% with a transaction volume of 269 million yuan. The financing buy amount for the day was 51.81 million yuan, while the financing repayment was 28.78 million yuan, resulting in a net financing buy of 23.03 million yuan. As of December 29, the total financing and securities lending balance was 586 million yuan [1] - The financing balance of Zhaoli Pharmaceutical on December 29 was 584 million yuan, accounting for 5.08% of the circulating market value, which is above the 70th percentile level over the past year, indicating a high position [1] - On the same day, Zhaoli Pharmaceutical repaid 800 shares in securities lending and sold 18,300 shares, with a selling amount of 300,100 yuan. The remaining securities lending volume was 133,700 shares, with a balance of 2.19 million yuan, exceeding the 90th percentile level over the past year, also indicating a high position [1] Group 2 - As of September 30, Zhaoli Pharmaceutical had 41,400 shareholders, an increase of 7.31% compared to the previous period. The average circulating shares per person decreased by 6.82% to 14,562 shares [2] - For the period from January to September 2025, Zhaoli Pharmaceutical achieved an operating income of 2.28 billion yuan, representing a year-on-year growth of 11.48%. The net profit attributable to the parent company was 510 million yuan, with a year-on-year increase of 21.00% [2] - Since its A-share listing, Zhaoli Pharmaceutical has distributed a total of 1.442 billion yuan in dividends, with 942 million yuan distributed in the last three years [3]

Core Viewpoint - The recent patent infringement lawsuit between Huadong Medicine and Zhaoli Pharmaceutical has concluded with Huadong Medicine's subsidiary losing the case, which involved over 1.11 billion yuan in claims, highlighting the competitive dynamics in the market for fermented Cordyceps sinensis products [1][7]. Group 1: Lawsuit Details - The lawsuit focused on the patent rights related to the invention of fermented Cordyceps sinensis powder and its formulations, with Huadong Medicine claiming infringement by Zhaoli Pharmaceutical's product, Bailin tablets [2][8]. - The Zhejiang High Court ruled that the accused products did not fall under the protection of the claimed patent, leading to the dismissal of all claims by Huadong Medicine and requiring them to pay over 590,000 yuan in court fees [3][10]. Group 2: Market Dynamics - The dispute reflects a significant market battle over the Bailin series, which has historically generated substantial revenue for Huadong Medicine, with sales peaking at 3.486 billion yuan in 2019 [4][11]. - Zhaoli Pharmaceutical has disrupted Huadong Medicine's market dominance by acquiring an 81% stake in Qinhai Zhu Feng Winter Worm Summer Grass Pharmaceutical Co., thus integrating Bailin tablets into its portfolio [5][12]. - Zhaoli Pharmaceutical's Bailin series has seen a 38.51% increase in sales revenue, aided by its inclusion in multiple national insurance and basic drug catalogs, indicating a rapid market penetration [5][12]. Group 3: Strategic Implications - The failed acquisition attempt by Huadong Medicine to gain control over Zhaoli Pharmaceutical in 2019 has intensified the competitive landscape, leading to a reliance on patent litigation as a defense strategy [6][12]. - Analysts suggest that the lawsuit's outcome is critical not only for the 1.11 billion yuan claim but also for Huadong Medicine's market influence in a sector valued at 30 billion yuan [6][12].

Core Viewpoint - The patent dispute between two listed pharmaceutical companies, Huadong Medicine and Zhaoli Pharmaceutical, centers on the ownership of the invention patent for fermented Cordyceps sinensis powder, which is a key ingredient in the Bailing capsule product line. The competition is intensifying as Zhaoli Pharmaceutical's Bailing capsule has been approved, breaking Huadong Medicine's previous monopoly in this market segment [3][5][10]. Group 1: Patent Dispute Details - Huadong Medicine's Bailing capsule previously generated annual sales exceeding 3 billion yuan, and the core ingredient is fermented Cordyceps sinensis powder [3][11]. - Huadong Medicine filed a lawsuit against Zhaoli Pharmaceutical and its subsidiaries, claiming patent infringement and seeking approximately 1.11 billion yuan in damages [5][6]. - The Zhejiang High Court ruled against Huadong Medicine in the first instance, dismissing all claims and ordering it to bear over 590,000 yuan in court fees [7][8]. Group 2: Market Impact and Financial Performance - The Bailing series, which includes Bailing capsules, Bailing granules, and Bailing tablets, is a significant market segment, with both companies nearly splitting the market [10][11]. - Huadong Medicine's Bailing capsule sales peaked at 3.486 billion yuan in 2019, but sales have since declined to around 1.8 billion yuan in 2022 due to price reductions [11][12]. - Zhaoli Pharmaceutical's Bailing tablet series generated 2.02 billion yuan in revenue in 2023, reflecting a 21.23% decline from the previous year due to competitive pressures [12][13]. Group 3: Future Prospects - Zhaoli Pharmaceutical aims to develop the Bailing series into a 1 billion yuan product line, indicating strong growth ambitions [15]. - The Bailing series, including both Bailing tablets and capsules, contributed 1.13 billion yuan in revenue in the first half of 2025, marking a 38.51% increase year-on-year [14]. - As of December 16, the market capitalization of Huadong Medicine was approximately 69.1 billion yuan, while Zhaoli Pharmaceutical's market cap was around 11.9 billion yuan [16].

Core Viewpoint - The article discusses the patent dispute between two listed pharmaceutical companies, Huadong Medicine and Zhaoli Pharmaceutical, focusing on the core ingredient of the Bailing capsule, which has historically generated significant sales revenue for Huadong Medicine [5][8]. Group 1: Patent Dispute Details - The lawsuit centers on the patent rights of fermented Cordyceps sinensis powder, which is the main ingredient in the Bailing capsule, previously a unique product for Huadong Medicine with annual sales exceeding 3 billion yuan [8][12]. - Huadong Medicine filed a lawsuit against Zhaoli Pharmaceutical and its subsidiaries, claiming infringement of its patent rights and seeking approximately 1.11 billion yuan in damages [11][12]. - The Zhejiang High Court ruled against Huadong Medicine in the first instance, dismissing all claims and ordering it to bear over 590,000 yuan in court fees [13][14]. Group 2: Market Competition - The competition between Huadong Medicine and Zhaoli Pharmaceutical is intensifying, with both companies nearly splitting the market for Bailing products [8][17]. - Huadong Medicine's Bailing capsule was a major product, achieving sales of over 3 billion yuan in 2019, but faced a decline in sales due to price reductions after being included in the medical insurance directory [17][18]. - Zhaoli Pharmaceutical, through acquisitions, has positioned itself in the Bailing market, with its Bailing tablet generating revenue of 2.02 billion yuan in 2023, down 21.23% from the previous year due to competitive pressures [18][19]. Group 3: Future Outlook - Zhaoli Pharmaceutical aims to grow its Bailing series into a 1 billion yuan product line, with expectations of increased revenue as the product gains market traction following its recent approval [19]. - As of December 16, 2023, Huadong Medicine's market capitalization was approximately 69.1 billion yuan, while Zhaoli Pharmaceutical's was around 11.9 billion yuan, indicating a significant disparity in market valuation [19].

Core Viewpoint - The lawsuit between two listed pharmaceutical companies regarding the patent rights of a high-revenue traditional Chinese medicine product has progressed, with the first-instance judgment rejecting all claims from the plaintiff, Huadong Medicine [1][3]. Group 1: Lawsuit Details - Huadong Medicine's subsidiary, Zhongmei Huadong Pharmaceutical, filed a lawsuit against three defendants, including Qinghai Zhu Feng Winter Worm Summer Grass Raw Material Co., Ltd., Qinghai Zhu Feng Winter Worm Summer Grass Pharmaceutical Co., Ltd., and Hangzhou Huadong Wulin Pharmacy Co., Ltd. [3][5]. - The lawsuit involves a patent related to the "enzyme, gene, and application of adenosine acid synthesis from Cordyceps sinensis," which Huadong Medicine claims is being infringed upon by the defendants [4][5]. - The disputed amount in the lawsuit is 110 million yuan, and Huadong Medicine plans to appeal the decision to the Supreme People's Court of China [1][3]. Group 2: Financial Implications - The sales revenue of the Bailing series, which includes Bailing capsules owned by Huadong Medicine, exceeded 3 billion yuan in 2019, indicating significant market presence [3][4]. - The Bailing series saw a year-on-year revenue growth of 38.51% in the first half of 2025, highlighting its competitive position in the market [3]. Group 3: Company Responses - In response to the lawsuit, the defendants, particularly Zhaoli Pharmaceutical, stated that they respect intellectual property rights and have conducted thorough due diligence regarding the patent issues related to the raw materials used in their products [6][7]. - Zhaoli Pharmaceutical emphasized that their production and sales of Bailing tablets comply with national laws and regulations, asserting that they do not infringe on Huadong Medicine's patent rights [6][7].

Core Viewpoint - The patent dispute between two listed pharmaceutical companies, Huadong Medicine and Zhaoli Pharmaceutical, centers on the invention patent rights of fermented Cordyceps sinensis powder, which is a key ingredient in Huadong's previously exclusive product, Bailing Capsules [2][4][5]. Group 1: Legal Proceedings - Huadong Medicine's subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical, received a civil judgment from the Zhejiang High Court, which dismissed all of Huadong's claims regarding the patent dispute [2][8]. - The case involved a claim for approximately 1.1139 billion yuan, which increased by 10,600 yuan from the initial disclosure [2][7]. - Huadong Medicine plans to appeal to the Supreme People's Court following the unfavorable ruling [4][9]. Group 2: Market Impact - The dispute is significant as it affects the market for Bailing products, which has historically generated substantial revenue, with Bailing Capsules achieving sales exceeding 30 billion yuan in previous years [4][11]. - Following the approval of Zhaoli Pharmaceutical's Bailing Capsules as a same-name product in January 2024, the market dynamics shifted, leading to a near equal division of the Bailing product line between the two companies [4][13]. - Zhaoli Pharmaceutical's Bailing series, including Bailing Capsules and Bailing Tablets, reported a combined revenue of 1.88 billion yuan in 2024, with expectations for future growth as they aim to establish the series as a 1 billion yuan product [12][14]. Group 3: Financial Performance - Huadong Medicine's Bailing Capsules had sales of 34.86 billion yuan in 2019, but faced a decline due to price reductions after being included in the medical insurance directory, stabilizing around 18 billion yuan in 2022 [11]. - Zhaoli Pharmaceutical's Bailing Tablets generated 2.02 billion yuan in revenue in 2023, reflecting a 21.23% decline due to competitive pressures and pricing strategies [12].

Core Viewpoint - Huadong Medicine's subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical, lost a first-instance patent infringement lawsuit, with the case amounting to approximately 111 million yuan [1] Group 1: Lawsuit Details - The lawsuit was initiated in 2023 due to a patent infringement dispute involving the core product, the fermented Cordyceps powder, which is a key ingredient in the Bailing capsule [2] - The Zhejiang High People's Court ruled against Huadong Medicine's claims, and the company plans to appeal the decision [1][2] - The court's decision is based on evidence presented during the trial, which Huadong Medicine disputes as not accurately reflecting the facts of the case [2] Group 2: Product Information - The Bailing capsule, a core product of Huadong Medicine, is used for treating conditions related to lung and kidney deficiencies, and it has been a unique offering in the market [2] - In 2017, the sales scale of the Bailing capsule reached 2 billion yuan, and in the first half of this year, it was among the top 20 traditional Chinese medicine brands in urban community markets, with sales exceeding 100 million yuan [3] - The product's main sales channels include public hospitals, community health centers, and township clinics across China [2] Group 3: Competitive Landscape - The Bailing capsule is now facing competition as Zhaoli Pharmaceutical, the parent company of the defendant in the lawsuit, has received regulatory approval for its own version of the product, breaking Huadong Medicine's previous monopoly [3] - Zhaoli Pharmaceutical's recent court ruling confirmed that its product does not infringe on Huadong Medicine's patent, which may impact Huadong's market position [3]